Reveal the Patterns of Presentation, Management and Outcome of Patients with SCLC and Stage III NSCLC in Saudi Arabia:

Trial Identifier:	D4191R00036
Sponsor:	AstraZeneca
NCTID::	NCT04836975
Start Date:	February 2022
Primary Completion Date:	December 2022
Study Completion Date:	December 2022
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Saudi Arabia	Dammam, Saudi Arabia
Saudi Arabia	Riyadh, Saudi Arabia

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.